Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
Tira Jing Ying TanSarah L SammonsYoung-Hyuck ImLilin SheKelly MundyRobert BigelowTiffany A TrainaCarey K AndersJoe Poh Sheng YeongEzequiel RenzulliSung-Bae KimRebecca A DentPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
PFS was longer than expected with both regimens. A patient subset with wild-type BRCA platinum-sensitive aTNBC had durable disease control with chemotherapy-free maintenance.